NCT03889106 is a clinical trial of Ribavirin in Lassa Fever, sponsored by University of Oxford.

Who is sponsoring NCT03889106?

NCT03889106 is sponsored by University of Oxford.

What drugs are being tested in NCT03889106?

Interventions in NCT03889106: Ribavirin.

What condition does NCT03889106 study?

NCT03889106 studies Lassa Fever.

Is NCT03889106 still recruiting?

NCT03889106 is currently terminated. Last updated 6 July 2022.

Last reviewed 2022-07-06 · How we verify

NCT03889106

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cardiovascular Function and Ribavirin Pharmacokinetics and Pharmacodynamics in Patients With Lassa Fever

Terminated Last updated 6 July 2022

What this trial tests

trial testing Ribavirin in Lassa Fever in 2 participants. Terminated before completion.

Timeline

1 March 2019

Primary endpoint
1 October 2020

1 October 2020

Quick facts

Lead sponsor	University of Oxford
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	2
Start date	1 March 2019
Primary completion	1 October 2020
Estimated completion	1 October 2020
Sites	1 location across Sierra Leone

Drugs / interventions tested

Ribavirin — full drug profile →

Conditions studied

Lassa Fever — all drugs for Lassa Fever →

Sponsor

University of Oxford

Who can join

10 and older, any sex, with Lassa Fever. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Lassa fever carries a treated mortality in hospitalized patients of up to 50%. Lassa fever is often described as being characterized by vascular leak and shock in the terminal phase, but, whilst animal data supports this, there are limited data in humans. Therefore, an aim of this study therefore is to characterize cardiovascular function in patients with Lassa fever, with the ultimate goal of informing future trials of supportive or therapeutic strategies. Ribavirin is the current standard of care. However, the efficacy of ribavirin has not been established in a randomised controlled trial (RCT). There is very limited pharmacokinetic (PK) data on ribavirin in patients with Lassa fever and the optimal dose of ribavirin for an RCT is unknown. Furthermore, there are various hypothesized mechanisms of action of ribavirin, none of which have been investigated in humans with Lassa fever. Further aims of this study therefore are to characterize the PK of ribavirin in Lassa fever, and identify any associations between ribavirin PK parameters, viral load and markers of immune/inflammatory status.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Treatment of highly virulent mammarenavirus infections-status quo and future directions.
Nuñez IA, Crane A, Crozier I, Worwa G, et al · · 2024 · cited 2× · PMID 38606475 · DOI 10.1080/17460441.2024.2340494

Verify or expand the search:

Other trials of Ribavirin

Trials testing the same drug.

NCT06744777 — The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Signi · Phase 3 · completed
NCT06488300 — Assessing Antiviral Treatments in Early Symptomatic RSV · Phase 2 · recruiting
NCT05940545 — UMIT-1 Trial Favipiravir & Ribavirin for the Treatment of CCHF · Phase 1, PHASE2 · unknown
NCT05717400 — Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Inf · Phase 4 · terminated
NCT04605588 — A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19 · Phase 2 · terminated

Other recruiting trials for Lassa Fever

Currently open trials in the same condition.

NCT03655561 — Lassa Fever Clinical Course and Prognostic Factors in Nigeria · active not recruiting

Other University of Oxford trials

Trials by the same sponsor.

NCT05380388 — A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 ) · Phase 2 · not yet recruiting
NCT07470424 — A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults · Phase 1 · not yet recruiting
NCT07345910 — Environment, Pathogens, and Host Interactions in Melioidosis · not yet recruiting
NCT07434973 — Stratification and Treatment in Early Psychosis Study - PROMOTE · Phase 3 · not yet recruiting
NCT07460401 — 'Do Patient Characteristics Associate With Poor Outcome With Femoral Acetabular Impingement Syndrome (FAIS) Following Ph · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03889106 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Oxford
Last refreshed: 6 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03889106.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing